New nano-systems capable of binding heparin as effectively as protamine

NewsGuard 100/100 Score

New nano-systems developed in York may eventually help patients recover from surgery without the danger of allergic reactions to drugs.

Researchers from the University of York's Department of Chemistry have developed synthetic molecules capable of binding the chemical drug heparin, which they believe may provide an alternative to protamine.

During surgery patients are given heparin to thin the blood and prevent clotting. However, once surgery is finished, it is essential to remove the heparin and allow clotting so the patient can recover. Currently this is done with the drug protamine, a natural product extracted from shellfish which can cause serious side effects in some patients.

The synthetic molecules created in York are designed to self-assemble into nanometre-sized structures with similar dimensions to protamine and containing multiple heparin binding units.

The results of the early stage study, published in Angewandte Chemie, show that the new nano-systems are capable of binding heparin just as effectively as protamine.

Professor Dave Smith, from the Department of Chemistry, said: "Clearly there is lots of fundamental work still to be done before clinical application. However, we hope that this approach may eventually yield biocompatible and degradable heparin binders which will help surgical recovery without any of the side effects which can be caused by protamine."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Bariatric surgery outperforms traditional treatments for long-term diabetes control